Eli Lilly Agrees to Acquire French Biotech Co. Mablink
Provided by
Dow Jones
By Ben Glickman
Eli Lilly agreed to acquire preclinical biotechnology company Mablink Bioscience.
Lyon, France-based Mablink, which develops antibody-drug conjugates, a new class of cancer drugs, said on Wednesday it had agreed to be acquired by Lilly. The company didn't disclose terms of the deal.
The transaction must be approved by the French Ministry of the Economy before closing.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 18, 2023 16:10 ET (20:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?